Effects of electrochemotherapy with cisplatin and peritumoral IL-12 gene electrotransfer on canine mast cell tumors: a histopathologic and immunohistochemical study

1Campana L, Clover AJP, Valpione S, Quaglino P, Gehl J, Kunte C, et al. Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiol Oncol 2016; 50: 1-12. doi:10.1515/raon-2016-0006CampanaLCloverAJPValpioneSQuaglinoPGehlJKunteC Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review Radiol Oncol 2016 50 1 12 doi:10.1515/raon-2016-0006Open DOISearch in Google Scholar

2Cemazar M, Tamzali Y, Sersa G, Tozon N, Mir LM, Miklavcic D, et al. Electrochemotherapy in veterinary oncology. J Vet Int Med 2008; 22: 826-31. 10.1111/j.1939-1676.2008.0117.xCemazarMTamzaliYSersaGTozonNMirLMMiklavcicD Electrochemotherapy in veterinary oncology J Vet Int Med 2008 22 82631 10.1111/j.1939-1676.2008.0117.xOpen DOISearch in Google Scholar

3Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall G, et al. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 2015; 64: 1315-27. 10.1007/s00262-015-1724-2SersaGTeissieJCemazarMSignoriEKamensekUMarshallG Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer Cancer Immunol Immunother 2015 64 1315 27 10.1007/s00262-015-1724-2Open DOISearch in Google Scholar

4Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, et al. Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radio Oncol 2012; 46: 302-11. 10.2478/v10019-012-0044-9SedlarADolinsekTMarkelcBProsenLKranjcSBosnjakM Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity Radio Oncol 2012 46 302 11 10.2478/v10019-012-0044-9Open DOISearch in Google Scholar

5Kishida T, Asada H, Itokawa Y, Yasutomi K, Shin-Ya M, Gojo S, et al. Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Mol Ther 2003; 8: 738-45.KishidaTAsadaHItokawaYYasutomiK Shin-YaMGojoS Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice Mol Ther 2003 8 738 45Search in Google Scholar

6Torrero MN, Henk WG, Li S. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin Cancer Res 2006; 12: 257-63. 10.1158/1078-0432.CCR-05-1514TorreroMNHenkWGLiS. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy Clin Cancer Res 2006 12 257 63 10.1158/1078-0432.CCR-05-1514Open DOISearch in Google Scholar

7Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Methods Mol Biol 2008; 423: 319-25. 10.1007/978-1-59745-194-9_24CutreraJTorreroMShiomitsuKMauldinNLiS. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs Methods Mol Biol 2008 423 319 25 10.1007/978-1-59745-194-9_24Open DOISearch in Google Scholar

8Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, et al. Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions. Curr Gene Ther 2015; 15: 44-54.CutreraJKingGJonesPKicenuikKGumpelEXiaX Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions Curr Gene Ther 2015 15 44 54Search in Google Scholar

9Cutrera J, King G, Jones P, Kicenuik K, Gumple E, Xia X, et al. Safe and effective treatment of spontaneous neoplasms with interleukin 12 electrochemo-gene therapy. J Cell Mel Med 2015, 19: 664-75. 10.1111/jcmm.12382CutreraJKingGJonesPKicenuikKGumpleEXiaX Safe and effective treatment of spontaneous neoplasms with interleukin 12 electrochemo-gene therapy J Cell Mel Med 2015 19 664 75 10.1111/jcmm.12382Open DOISearch in Google Scholar

10Pavlin D, Cemazar M, Coer A, Sersa G, Pogacnik A, Tozon N. Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol 2011; 45: 31-9. 10.2478/v10019-010-0041-9PavlinDCemazarMCoerASersaGPogacnikATozonN. Electrogene therapy with interleukin-12 in canine mast cell tumors Radiol Oncol 2011 45 31 9 10.2478/v10019-010-0041-9Open DOISearch in Google Scholar

11Cemazar M, Ambrozic Avgustin J, Pavlin D, Sersa G, Poli A, Krhac Levacic A, et al. Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 electrotransfer of canine mast cell tumors. Vet Comp Oncol 2017; 15: 641-4. 10.1111/vco.12208CemazarM Ambrozic AvgustinJPavlinDSersaGPoliA Krhac LevacicA Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 electrotransfer of canine mast cell tumors Vet Comp Oncol 2017 15 641 4 10.1111/vco.12208Open DOISearch in Google Scholar

12Pavselj N, Preat V. DNA electrotransfer into the skin using a combination of one high- and one low-voltage pulse. J Control Release 2005; 106: 407-15. 10.1016/j.jconrel.2005.05.003PavseljNPreatV. DNA electrotransfer into the skin using a combination of one high- and one low-voltage pulse J Control Release 2005 106 407 15 10.1016/j.jconrel.2005.05.003Open DOISearch in Google Scholar

13Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol 2011; 48: 147-55. 10.1177/0300985810386469KiupelMWebsterJDBaileyKLBestSDeLayJDetrisacCJ Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior Vet Pathol 2011 48 147 55 10.1177/0300985810386469Open DOISearch in Google Scholar

14Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin- DNA adducts. Chem Rev 1999; 99: 2467-98.JamiesonERLippardSJ. Structure, recognition, and processing of cisplatin- DNA adducts Chem Rev 1999 99 2467 98Search in Google Scholar

15Scarfò L, Ghia P. Reprogramming cell death. BCL2 family inhibition in hematological malignancies. Immunol Lett 2013; 155: 36-9. 10.1016/j.imlet.2013.09.015ScarfòLGhiaP. Reprogramming cell death. BCL2 family inhibition in hematological malignancies Immunol Lett 2013 155 36 9 10.1016/j.imlet.2013.09.015Open DOISearch in Google Scholar

16Belehradek J, Orlowski S, Poddevin B, Paoletti C, Mir LM. Electrochemotherapy of spontaneous mammary tumours in mice. Eur J Cancer 1991; 27: 73-6.BelehradekJOrlowskiSPoddevinBPaolettiCMirLM. Electrochemotherapy of spontaneous mammary tumours in mice Eur J Cancer 1991 27 73 6Search in Google Scholar

17Sersa G, Jarm T, Kotnik T, Coer A, Podkrajek M, Sentjurc M. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008; 98: 388-98. 10.1038/sj.bjc.6604168SersaGJarmTKotnikTCoerAPodkrajekMSentjurcM. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma Br J Cancer 2008 98 388 98 10.1038/sj.bjc.6604168Open DOISearch in Google Scholar

18Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46. 10.1038/nri1001TrinchieriG. Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat Rev Immunol 2003 3 133 46 10.1038/nri1001Open DOISearch in Google Scholar

19Cutrera J, Li S. Passive and active tumor homing cytokine therapy. In: Lustgarten J, Cui Y, Li S, editors. Targeted cancer immune therapy. New York: Springer; 2009. p. 97-113.CutreraJLiS. Passive and active tumor homing cytokine therapy LustgartenJCuiYLiS Targeted cancer immune therapy New York Springer 2009 97113Search in Google Scholar

20Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-85. 10.1158/1078-0432.CCR-07-0776Del VecchioMBajettaECanovaSLotzeMTWesaAParmianiG Interleukin-12: biological properties and clinical application Clin Cancer Res 2007 13 4677 85 10.1158/1078-0432.CCR-07-0776Open DOISearch in Google Scholar

21Tamzali Y, Borde L, Rols MP, Golzio M, Lyazrhi F, Teissie J. Successful treatment of equine sarcoids with cisplatin electrochemotherapy: a retrospective study of 48 cases. Equine Vet J 2012; 44: 214-20. 10.1111/j.2042-3306.2011.00425.xTamzaliYBordeLRolsMPGolzioMLyazrhiFTeissieJ. Successful treatment of equine sarcoids with cisplatin electrochemotherapy: a retrospective study of 48 cases Equine Vet J 2012 44 214 20 10.1111/j.2042-3306.2011.00425.xOpen DOISearch in Google Scholar

22Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune provolege and predicts reduced survival. Nat Med 2004; 10: 942-9. 10.1038/nm1093CurielTJCoukosGZouLAlvarezXChengPMottramP Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune provolege and predicts reduced survival Nat Med 2004 10 942 9 10.1038/nm1093Open DOISearch in Google Scholar

23Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patient. Int J cancer 2009, 125: 1640-8. 10.1002/ijc.24556ZhouJDingTPanWZhuLYLiLZhengL. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patient Int J cancer 2009 125 1640 8 10.1002/ijc.24556Open DOISearch in Google Scholar

24Kim JH, Hur JH, Lee SM, Im KS, Kim NH, Sur JH. Correlation of Foxp3 positive regulatory T cells with prognostic factors in canine mammary carcinomas. Vet J 2012; 193: 222-7. 10.1016/j.tvjl.2011.10.022KimJHHurJHLeeSMImKSKimNHSurJH. Correlation of Foxp3 positive regulatory T cells with prognostic factors in canine mammary carcinomas Vet J 2012 193 222 7 10.1016/j.tvjl.2011.10.022Open DOISearch in Google Scholar

25Oh SY, Ryu HH, Yoo DY, Hwang IK, Kweon OK, Kim WH. Evaluation of FOXP3 expression in canine mammary gland tumours. Vet Comp Oncol 2014; 12: 20–8. 10.1111/j.1476-5829.2012.00327.xOhSYRyuHHYooDYHwangIKKweonOKKimWH. Evaluation of FOXP3 expression in canine mammary gland tumours Vet Comp Oncol 2014 12 20 8 10.1111/j.1476-5829.2012.00327.xOpen DOISearch in Google Scholar

26Li Q, Virtuoso LP, Anderson CD, Egilmez NK. Regulatory rebound in IL-12 treated tumors is driven by uncommitted peripheral regulatory T cells. J Immunol 2015, 195: 1293-1300. 10.4049/jimmunol.1403078LiQ VirtuosoLP AndersonCD EgilmezNK. Regulatory rebound in IL-12 treated tumors is driven by uncommitted peripheral regulatory T cells J Immunol 2015 195 12931300 10.4049/jimmunol.1403078Open DOISearch in Google Scholar